Patent intelligence · US
US 7704509
Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA and use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA and use of recombinant HPIV1 in immunogenic compositions and as v…
Patent details — US 7704509
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 27, 2010
- Expiration
- Apr 22, 2030
- Applicant
- The United States of America
- Claims
- 270
- CPC classes
- A61K, A61K2039/525, A61P, A61P31/14
Quick answer
US 7704509 (Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA and use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens) is held by The United States of America. Status: granted. Granted Apr 27, 2010. Expires Apr 22, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- The United States of America
- Grant date
- Expiration
- Claims
- 270
- CPC classes
- A61K, A61K2039/525, A61P, A61P31/14
More from The United States of America
Related pharmaceutical patents in our USPTO index.
-
US 12419873
Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
granted -
US 12419941
Poultry drinking water-based vaccine delivery system and method
granted -
US 12415845
Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
granted -
US 12410240
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
granted -
US 12410259
CD47 targeted therapies for the treatment of infectious disease
granted -
US 12404317
T cell receptors recognizing MHC class II-restricted MAGE-A3
granted -
US 12397066
Delivery of gene therapy treatments
granted -
US 12398123
Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria
granted
Frequently asked questions
What is US patent 7704509?
US 7704509 (Recovery of recombinant human parainfluenza virus type 1 (HPIV1) from cDNA and use of recombinant HPIV1 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens) is held by The United States of America. Status: granted. Granted Apr 27, 2010. Expires Apr 22, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7704509?
The United States of America is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3,720 pharmaceutical patents for this assignee.
When does US 7704509 expire?
Our index shows an expiration date of Apr 22, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.